Security key
320703408
Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI)
CUSIP: 320703408
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Total 13F shares
- 2,007,879
- Total 13F value
- $478,788
- Share change
- +1,559,557
- SEC-reported price per share
- $0.24
- Number of holders
- 27
- Value change
- +$226,762
- Number of buys
- 12
- Number of sells
- 8
- Shares outstanding
- 7,142,857
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
27
Top holders
10
CLDI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Calidi Biotherapeutics, Inc. SEC filings
Calidi Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 320703408
Recent filing periods:
Ownership snapshot
Top reported holders of CLDI - Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
10%
Gavrilov Ognian Anguelov
0.3%
Lincoln Alternative Strategies LLC
6.6%
Allan Camaisa
1.1%
DRW Securities, LLC
2.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
10%
|
$655,922
1,111,732 shares
|
-$1,326,278 | 31 Mar 2026 |
| Gavrilov Ognian Anguelov |
13D/G
|
0.3%
|
$6,600
20,000 shares
|
-$224,400 | 31 Mar 2026 |
| Lincoln Alternative Strategies LLC |
3/4/5
10%+ Owner
|
6.6%
|
$430,700
730,000 shares
|
— | 20 Aug 2025 |
| Allan Camaisa |
3/4/5
Director
|
1.1%
|
$111,965
76,952 shares
|
-$1,237 | 12 Dec 2025 |
| DRW Securities, LLC |
13F
Company
|
2.1%
|
$172,887
147,767 shares
|
— | 31 Dec 2025 |
| HighTower Advisors, LLC |
13F
Company
|
1.2%
|
$97,722
83,523 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
27
Shares
2,007,879
Rows available
27
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
27
Q1 2026 holders
27
Holder diff
0
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend